INTRODUCTION

54
The skin is an attractive route for the administration of drugs intended for both local and systemic 55 effects (Campbell, et al. 2012 ). In particular, the topical route for local treatment lowers the risk of 56 systemic side effects, because the stratum corneum (SC), the most superficial skin layer, provides a 57 significant barrier to drug penetration (Curdy, et al. 2004) . Given that nanoparticles (NP) larger than 58 10 nm are unable to penetrate either intact or partially impaired skin to any great extent (Campbell, 59 et al. 2012; Prow, et al. 2011 ), novel drug delivery systems for local effect based on this technology 60 have been proposed as topical reservoirs from which the sustained release of an active compound 61 may be achieved over a prolonged period of time. These characteristics support a strategy, therefore, 62 of using biodegradable, drug-loaded nanoparticles for the topical treatment of skin disease-63 associated lesions and chronic wounds.
64
The administration of growth factors, such as epidermal growth factor (EGF), to accelerate wound 65 healing has been extensively described (Choi, et wounded animal model has been reported (Gainza, et al. 2014 ).
74
The topical administration of a NP-based delivery system may be facilitated by their incorporation 75 into either semi-solid hydrogels or solid scaffolds. Bioadhesive hydrogels (e.g., Noveon ® AA-1 76 polycarbophil, a high molecular weight polymer of acrylic acid chemically cross-linked with divinyl 77 glycol) are widely used as wound dressings and their prolonged residence time in the skin offers the 78 opportunity for sustained drug release (Ceschel, et al. 2001; Padamwar, et al. 2011 Dorsal, full-thickness porcine skin was obtained post-sacrifice from locally sourced female pigs.
109
The skin was cleaned under cold running water and the subcutaneous fat was removed with a scalpel.
110
The remaining tissue was then dermatomed to a thickness of ~750 μm and stored frozen at -20°C
111
for up to at most one month before use. 
Lipid nanoparticle (NP) preparation
113 rhEGF-SLN and rhEGF-NLC were prepared as previously described (Gainza, et al. 2014 particles were collected, washed and freeze-dried as previously described.
127
In the experiments examining the disposition of the nanoparticles on the skin, the lipid phase of the 
Nanoparticle characterisation
144
The nanoparticles in the formulations were characterised (Zetasizer Nano ZS, Malvern Instruments, The encapsulation efficiency (EE) of rhEGF was determined indirectly by measuring the 150 concentration of free protein removed in the filtration/centrifugation step described in section 2.3.
151
The rhEGF assay used a commercially available sandwich enzyme-linked immunosorbent kit control. Measurements on 1 ml samples were made in triplicate at 0.5, 1, 2.5 and 5 rpm. 
Occlusivity test
162
The protocol for this in vitro test was adapted from one previously described (Souto, et al. 2004 ).
163
Franz cells were filled with 5 ml of water and covered with a cellulose membrane (D9652,
164
MWCO~12,000, Sigma-Aldrich, Madrid, Spain). 5 mg of NP in the reconstituted suspensions, the 165 Noveon ® AA-1 and Pluronic F-127 hydrogels, and the fibrin scaffold were applied to the exposed 166 surface of the cellulose membrane and the system was maintained at 32ºC for 48 h. Water loss from 167 the Franz cell was determined gravimetrically and compared to that when no formulation was 168 applied to the membrane. An occlusion factor (F) was calculated from the results using the following 
177
Release of the active was measured over one week at 32ºC, 0.5 ml samples of the receptor solution 
198
The uptake and permeation of rhEGF from the various NP formulations through the compromised 
RESULTS AND DISCUSSION
215
rhEGF-SLN and rhEGF-NLC characterisation, rheological studies and occlusion tests. 216
The topical disposition of nanoparticles is related to particle size and skin integrity (Jensen, et systemic uptake. Table 1 shows that all the nanoparticles studied in this work were similar in size
223
(320-350 nm in diameter) and not expected, therefore, to penetrate the skin, whether neither intact 
231
The pH values of the NP formulations fell within the 4-7 range recommended for topical products 232 (Duncan, et al. 2013 ) ( Table 2 ). The rheology and occlusivity results show that rhEGF-SLN and 233 rhEGF-NLC had similar properties ( Table 2) . As expected, all hydrogels had significantly higher 234 viscosities (p < 0.05) than the suspensions, suggesting that the former would have an increased 235 residence time at a wound site and permit the prolonged release of rhEGF.
236
The SLN-based suspensions and the integrated wound dressing-delivery systems were more 237 occlusive than those prepared with NLC (Table 2) 
Penetration of rhEGF into stratum corneum
268
Uptake of rhEGF from the various formulations into the stratum corneum (SC) was assessed by 269 tape-stripping after a 48 h exposure. All the NP-based formulations (whether with SLN or NLC, the 270 performance of which were very similar) resulted in greater uptake of rhEGF into the SC than 271 treatment with a simple solution of the protein (Table 3) , even though release from the integrated 272 wound dressing-drug delivery systems was far from complete in this time period (as discussed above 273 see Figure 2 ). However, regardless of the formulation, most of the rhEGF taken up into the SC was 274 constrained to the skin surface, i.e., was resident on the first tape-strip ( Figure 3A) , with very little 275 retrieved from the subsequent 11 strips ( Figure 3B ). Taken together, these results imply that there 
Uptake of rhEGF into damaged skin
285
The uptake of rhEGF from the formulations examined into skin samples from which the SC had 286 been essentially removed prior to dosing is shown in Table 3 . The recovery of the protein was higher 287 from all the wound dressing-drug delivery systems, and from the reconstituted NP suspensions, than For each type of wound dressing considered (i.e., the two hydrogels and the 291 fibrin scaffolds), the uptake of rhEGF was independent of the type of lipid used (SLC or NLC).
292
Protein uptake was highest from the simple NP suspensions, presumably due to the faster release of observed that the fibrin vehicles adhered particularly well to the skin suggesting that this formulation 298 may be able to prolong rhEGF residence time at the wound site. is that it can be released from the NP, dye the skin and give unreal information of the NP penetration.
306
For this reason, 16-NBD palmitic acid (16-NBD), a fluorescent lipid, which labels the NP directly,
307
was used to give an accurate localization of NP in the skin. In this regard, the LSCM study also 308 seeks to investigate the differences between labeling NP with NR or 16-NBD palmitic acid. the SC even when the skin was partially damaged by tape stripping (Campbell, et al. 2012) . No 316 influence of the vehicle was apparent.
317
For the NP applied as a suspension and in the Noveon ® AA-1 hydrogel, the release of the NR and 318 its subsequent penetration into the deeper skin layers was apparent (illustrated with the white circle 319 in Figure 5 ). This observation is consistent with the rhEGF skin uptake results discussed above and 320 with data from earlier work, which used NR as a model active to probe drug delivery from topically visualize because the reflectance images of the fibrin layer and of the skin were very similar. As a 327 result, and exacerbated by the strong interaction/adhesion between the fibrin scaffold and the skin,
328
it was impossible to define with any accuracy the location of the interface between the two. illustrates the dye penetration into the skin.
